Navigating AI in Healthcare: Expert Insights and FDA Draft Guidance
Guillaume Gigon
Vice-President, Technology and AI
Navigating AI risks in healthcare just got easier with the FDA’s new draft guidance and explanations from Guillaume Gigon, Innovaderm’s VP of Technology and AI.
You can even comment on the FDA draft document by April 7.
We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.